Back to News
Market Impact: 0.15
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Source: Business Wire
Healthcare & Biotech
Incyte and Genmab announced a clinical trial collaboration in metastatic colorectal cancer. The headline provides no details on the trial design, timing, or financial terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
GMAB0.50
INCY0.50
More News
- Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
- Biotech stocks are surging. How investors can play the new drug innovation boom
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
- J&J prostate cancer drug shows promising tumor responses in early trial
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer